Cartesian Therapeutics In Share Price Today: Live Updates & Key Insights

Cartesian Therapeutics In share price today is $6.51, up -0.91%. The stock opened at $6.42 against the previous close of $6.57, with an intraday high of $6.7 and low of $6.4.

Cartesian Therapeutics In Share Price Chart

Cartesian Therapeutics In

us-stock
To Invest in {{usstockname}}
us-stock

Cartesian Therapeutics In Share Price Performance

$6.51 -0.0091(-0.91%) RNAC at 23 Mar 2026 03:03 PM Biotechnology
Lowest Today 6.4
Highest Today 6.7
Today’s Open 6.42
Prev. Close 6.57
52 Week High 16.62
52 Week Low 5.98
Day’s Range: Low 6.4 High 6.7
52-Week Range: Low 5.98 High 16.62
1 day return -
1 Week return -11.7
1 month return -7.54
3 month return -3.42
6 month return -35.67
1 year return -59.36
3 year return -84.54
5 year return -95.35
10 year return -

Cartesian Therapeutics In Institutional Holdings

FMR Inc 5.16

BlackRock Inc 2.45

Vanguard Group Inc 2.04

Fidelity Growth Compy Commingled Pl S 1.73

HBM Healthcare Investments AG Ord 1.57

MPM Oncology Impact Management LP 1.43

Fidelity Select Biotechnology 1.38

Fidelity Growth Company Fund 1.28

Vanguard Total Stock Mkt Idx Inv 1.06

683 Capital Management LLC 1.06

Erste Asset Management GmbH 1.03

Geode Capital Management, LLC 0.96

iShares Russell 2000 ETF 0.92

State Street Corp 0.75

Marshall Wace Asset Management Ltd 0.67

Privium Fund Management B.V. 0.65

Millennium Management LLC 0.62

Vanguard Institutional Extnd Mkt Idx Tr 0.43

Fidelity Growth Company K6 0.40

Fidelity Small Cap Index 0.39

Jacobs Levy Equity Management, Inc. 0.36

Northern Trust Corp 0.34

Two Sigma Investments LLC 0.34

iShares Russell 2000 Value ETF 0.33

Citadel Advisors Llc 0.30

Fidelity Series Growth Company 0.30

GSA Capital Partners LLP 0.29

SSgA Russell Small Cap Completeness Idx 0.24

State St Russell Sm/Mid Cp® Indx SL Cl I 0.23

Fidelity Extended Market Index 0.22

Vanguard Russell 2000 ETF 0.19

Walleye Trading Advisors, LLC 0.17

Renaissance Technologies Corp 0.16

Royal Bank of Canada 0.14

State St Russell Sm Cap® Indx SL Cl I 0.12

iShares Micro-Cap ETF 0.11

XTX Topco Ltd 0.10

Bridgeway Ultra-Small Company Market 0.09

Schwab Small Cap Index 0.09

NT R2000 Index Fund - NL 0.09

Cartesian Therapeutics In Market Status

Strong Buy: 4

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Cartesian Therapeutics In Fundamentals

Market Cap 169.28 M

PB Ratio 31.2575

PE Ratio 0.0

Enterprise Value 38.50 M

Total Assets 296.41 M

Volume 106531

Cartesian Therapeutics In Company Financials

Annual Revenue FY23:34533000 34.5M, FY22:110777000 110.8M, FY21:85077000 85.1M, FY20:16597000 16.6M, FY19:6677000 6.7M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-36159000 -36.2M, FY22:35379000 35.4M, FY21:-25687000 -25.7M, FY20:-68876000 -68.9M, FY19:-55350000 -55.4M

Quarterly Revenue Q3/2025:452000 0.5M, Q2/2025:298000 0.3M, Q1/2025:1100000 1.1M, Q3/2024:387000 0.4M, Q2/2024:33445000 33.4M

Quarterly Profit Q3/2025:-12345000 -12.3M, Q2/2025:298000 0.3M, Q1/2025:1100000 1.1M, Q3/2024:387000 0.4M, Q2/2024:33249000 33.2M

Quarterly Net worth Q3/2025:-35902000 -35.9M, Q2/2025:15886000 15.9M, Q1/2025:-17710000 -17.7M, Q3/2024:-24183000 -24.2M, Q2/2024:13836000 13.8M

About Cartesian Therapeutics In & investment objective

Company Information Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Organisation Biotechnology

Employees 75

Industry Biotechnology

CEO Dr. Carsten Brunn Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Cartesian Therapeutics In FAQs

What is the share price of Cartesian Therapeutics In today?

The current share price of Cartesian Therapeutics In is $6.51.

Can I buy Cartesian Therapeutics In shares in India?

Yes, Indian investors can buy Cartesian Therapeutics In shares by opening an international trading and demat account with Motilal Oswal.

How to buy Cartesian Therapeutics In shares in India?

You can easily invest in Cartesian Therapeutics In shares from India by:

Can I buy fractional shares of Cartesian Therapeutics In?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Cartesian Therapeutics In?

Cartesian Therapeutics In has a market cap of $169.28 M.

In which sector does Cartesian Therapeutics In belong?

Cartesian Therapeutics In operates in the Biotechnology sector.

What documents are required to invest in Cartesian Therapeutics In stocks?

To invest, you typically need:

What is the PE and PB ratio of Cartesian Therapeutics In?

The PE ratio of Cartesian Therapeutics In is N/A and the PB ratio is 31.26.